Skip to content
Screener

Zoetis ZTS Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$2.3BMiss by $39.4M
EPS$1.53Miss by $0.07
Revenue estimate$2.3B
EPS estimate$1.60

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$2.3B
EPS estimate$1.51

Financials

Q1 2026

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$49.9B-32.3%
Enterprise value$57.95B-26.4%
P/E18.8×-10.8×
P/S5.2×-2.7×

Profitability

See full
Gross margin71.6%+0.7pp
Net margin27.8%+1.0pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67.2%+16.0pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Segments

By product

See full
Parasiticides$586.0M+2.4%
Vaccines$519.0M+18.2%
Dermatology$349.0M-7.9%
Anti-infectives$241.0M+1.3%
Pain and sedation$203.0M-1.9%

By segment

See full
International$1.1B+16.6%
U.S.$1.1B-7.9%

FAQ

When did Zoetis report Q1 2026 earnings?
Zoetis (ZTS) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Zoetis's Q1 2026 revenue and EPS?
Zoetis reported revenue of $2.3B and eps of $1.53 for Q1 2026.
Did Zoetis beat estimates in Q1 2026?
Revenue missed the consensus estimate of $2.3B by $39.4M. EPS missed the consensus estimate of $1.60 by $0.07.
How did Zoetis's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.9% from $2.2B a year earlier and eps grew 3.4% from $1.48.
Where can I find Zoetis's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001555280-26-000021) and the 10-Q periodic report (0001555280-26-000024) directly on SEC EDGAR. The filing index links above go to sec.gov.